Financebotresearch desk研究台

CTSH › analyze

CTSH · Analyze

Technology

Date: 2026-07-09 | Price: $43.33 (52wk range $37.08–$87.03, down 44.7% over 1yr / ~46% YTD) | Sector: Technology / IT Services | Market Cap: $20.5B

Conviction: [6.5] — Statistically cheap, structurally challenged. Value case, not a slam dunk.


1. Fundamentals (Fundamentals Analyst)

Free Cash Flow

FY Revenue Net Income OCF CapEx FCF FCF/share
2022 $19.43B $2.29B $2.57B -$0.33B $2.24B $4.39
2023 $19.35B $2.13B $2.33B -$0.32B $2.01B $4.02
2024 $19.74B $2.24B $2.12B -$0.30B $1.83B $3.69
2025 $21.11B $2.23B $2.88B -$0.29B $2.60B $5.42
  • FCF CAGR (2022–2025, 3yr): ~5.1%/yr raw; FCF/share CAGR ~7.3%/yr — the buyback engine is doing real work compounding per-share value even though absolute FCF wobbled through 2023–24.
  • ⚠️ Note: trailing-twelve-month freeCashflow from the live quote feed shows $1.91B — lower than FY2025's $2.60B. This reflects Q1 2026 seasonality (working-capital swings, timing of tax payments) rather than a change in trend; FY-based figures are used above for CAGR integrity.

Capital Allocation (FY2025, $2.88B OCF)

Use Amount % of OCF
CapEx (reinvestment) $0.29B 10%
Buybacks $1.38B 48%
Dividends $0.61B 21%
Debt paydown (net) $0.34B 12%
M&A / investing (net) ~$0

Disciplined allocator: minimal M&A, no empire-building, cash returned almost entirely to shareholders. Management just raised the 2026 buyback authorization by $1B to $2B (announced May 18) — ~10% of current market cap — a real signal of insider conviction the stock is cheap, funded entirely from balance-sheet cash, not debt.

Balance Sheet & Leverage

  • Total debt: $1.15B vs. total assets $20.7B → debt-to-assets ~5.6% — very low leverage.
  • Cash & equivalents: $1.90B — company is effectively net-cash.
  • Current ratio 2.23x, quick ratio 1.74x — ample liquidity.

Shares Outstanding (tailwind)

509M (2022) → 498M (2023) → 495M (2024) → 479M (2025), a cumulative -5.9% over 3 years, accelerating to -3.2% in the most recent year. Buybacks are outrunning dilution and will keep doing so at this valuation.

Top/Bottom Line

  • Revenue CAGR 2022–2025: ~2.8%/yr (accelerated to +5.8% YoY reported / +3.9% cc in Q1 2026, upper half of guidance).
  • Net income roughly flat (2.29B → 2.23B), diluted EPS grew 4.41 → 4.56 (+1.1%/yr) — buybacks are the entire story on the bottom line; organic profit growth has stalled.
  • Q1 2026: adjusted EPS $1.40, +13.8% YoY on cost discipline. FY2026 guidance: 4.0–6.5% cc revenue growth, adjusted operating margin raised to 16.0–16.2% (+20-40bps), driven by new Project Leap cost program ($200–300M savings in 2026, funding 12,000–15,000 headcount reduction, ~4-5% of workforce).

Data flags

  • Forward EPS ($6.19) implies ~34% growth over trailing EPS ($4.61) — this is the Street's number, driven by assumed margin expansion + buybacks. Treat with skepticism; it has not yet been earned. Graham/Bogle below use trailing, not forward, figures for conservatism.

2. Moat & Competitive Advantage (Moat Analyst)

Quantitative base

2022 2025 Trend
Gross margin 35.9% 33.7% ↓ -220bps over 3yrs
ROIC (NOPAT/Invested Capital) ~17.8% ~14.4% ↓ -340bps over 3yrs

Both moat proxies are eroding, not stable. This is not noise — it is the direct fingerprint of pricing/margin pressure in the core business.

Adversarial stress-test

"You are a well-funded rival — how easily do you disrupt Cognizant?" Uncomfortably easily, in the specific slice of the business that has historically funded the whole pyramid: legacy application maintenance, testing, and migration work billed by the hour on junior staff. AI coding assistants and agentic workflows directly substitute for that labor. Cognizant is not hypothetically threatened — it is already restructuring in response, cutting 12–15k jobs and admitting the traditional headcount-pyramid model is breaking. That is a company-level acknowledgment that the moat (switching costs + scale + relationship depth) no longer fully protects margin the way it used to.

Revenue-stream map

Four segments: Financial Services (leading growth, +12% YoY, 7 large deals, +70% large-deal TCV growth), Health Sciences, Products & Resources, Communications/Media/Tech. Diversified by vertical, which helps durability, but all four segments monetize via the same underlying services/staff-augmentation model that is under structural pressure.

Disruption forecast

  • 1–3yr: AI-assisted development (Cognizant itself reports ~40% of code now AI-assisted, 5,000+ AI engagements) compresses billable hours in exactly the practice areas that generate the bulk of revenue. Every large IT services peer (ACN, INFY, WIT, EPAM) faces the identical thesis — this is a sector repricing, not a CTSH-specific failure.
  • 5–10yr: Plausible evolution toward higher-value, IP-driven work — Cognizant Neuro AI Trust (AI governance platform), partnerships with Google Cloud/Gemini Enterprise, OpenAI, and Domyn (sovereign AI, EMEA) are the company's bet on capturing the next model. Credible moves, but unproven at scale — no disclosed ARR or margin contribution yet.

Evergreen assessment

Not evergreen in its current form. The 2010s pyramid-staffing model is being dismantled in real time by the company that built it. What survives is scale, balance-sheet strength, deep vertical client relationships (multi-year embedded contracts = real switching costs), and now an AI-partnership strategy — but the margin structure of the surviving business is likely permanently different (lower) than the one the stock's 2021 all-time high ($93) was priced for.

Moat-defense evaluation

Management is playing defense correctly on paper: cost-cutting ahead of the pain (Project Leap), leaning into partnerships rather than denial, and putting $2B of cash behind the stock. Risk/reward on this defense is reasonable but not proven — judge it on execution over the next 2-3 quarters (bookings mix shifting to AI-native deals, margin guidance holding).


3. Sentiment & Intelligence (Sentiment Analyst)

What actually happened to the stock

The ~46% YTD decline was not triggered by a CTSH-specific miss. Q1 2026 beat expectations (revenue $5.41B, +5.8% YoY, upper half of guidance; adjusted EPS +13.8%), and management raised full-year margin guidance. The drawdown was driven by: 1. Sector-wide re-rating — Accenture tightened its own full-year growth target in June, spooking the entire IT-services complex. 2. Berenberg downgrade (Buy→Hold, PT $81→$59) explicitly citing "a faster-than-expected AI transition that has materially worsened the structural outlook for legacy IT services providers" — this is the crux of the bear case, and it's a real, not manufactured, concern. 3. Nasdaq-100 index exit (June 22) — mechanical, forced index-fund selling, unrelated to fundamentals. 4. Broad multiple compression across IT-services peers on the same AI-disruption narrative.

Analyst coverage — genuinely split

25 analysts, mean rating "Buy" (2.17), but price targets range $42–$88 (mean $67, median $68) — one of the widest dispersions on the Watchlist. Recent target cuts (TD Cowen $62→$47, Morgan Stanley $63→$44, late June) are the most bearish and closest to the current price — i.e., the analysts marking-to-market most recently are the most cautious. Conversely, Wedbush upgraded to Outperform ($56→$70) on June 8, and Citi nudged its target up to $55 on June 9. No consensus on where this settles.

Insider activity

Pattern is routine, scheduled small officer sales (10b5-1-style, same handful of names selling small tranches every pay period, all the way down from $85 to $40 — not a signal either way). One notable exception: Director Stephen Rohleder bought 4,034 shares ($210K) at $52.00 on June 10 — a genuine open-market purchase, a modest golden flag, though it predates the stock's continued slide to $43. No cluster of insider buying at current levels yet.

Short interest — a real bearish signal

Shares short jumped from 47.4M to 59.8M month-over-month (12.7% of float, short ratio 6.4 days-to-cover). This is meaningfully elevated and rising — the market has a live, well-funded bear thesis, not just noise. It also means any positive surprise (bookings mix, margin proof-point) has real short-squeeze fuel.

AI partnership newsflow (past 2 weeks)

Active push: expanded Google Cloud/Gemini Enterprise partnership, new "Cognizant Neuro AI Trust" governance platform, Domyn alliance for sovereign AI in EMEA. Positive direction, no disclosed financial impact yet — treat as pipeline, not proof.


4. Valuation (Valuation Analyst)

Dividend-grower overlay applies (3.11% yield, 27% payout, consistent raises). Type: large-cap, profitable, moderate growth — Graham + Bogle carry primary weight; DYT and DDM applicable given the reliable dividend history but sensitive to growth/discount-rate assumptions.

Model Inputs Output
Graham Intrinsic Value EPS $4.56 (FY2025 diluted, trailing), BVPS $31.79 √(22.5 × 4.56 × 31.79) ≈ $57
Dividend Yield Theory Current yield 3.11% vs. 5yr avg yield 1.59% Yield is ~2x its own 5yr average — historically a strong undervaluation signal, if the dividend is safe (payout ratio 27% says it is)
DDM (Gordon Growth) D1 ≈ $1.41 (6.6%/yr historical div CAGR), r = 9–10% Wide range $28–$59 depending on r−g spread — flagged as low-precision given how sensitive DDM is near a narrow r−g gap
Bogle Expected Return Div yield 3.1% + conservative EPS growth 5-7% (mgmt guidance-based, not the aggressive Street forward number) ± flat P/E ~8-10%/yr expected return, before any multiple re-rating

Fair value range: ~$45–$60, centered around Graham's $57, with the DYT signal corroborating undervaluation and DDM's wide band reflecting genuine uncertainty. Current price of $43.33 sits below this range — a margin of safety exists, but it is a value case resting on the market's AI-disruption fear being overstated, not a case where the business quality itself is uncontested (see §0 first-principles: this is the "close call" quadrant, not clean "great + cheap").

Trailing P/E 9.4x, forward P/E 7.0x (on an aggressive forward EPS number — treat forward multiple with caution), FCF yield on FY2025 FCF ≈ 12.7% ($2.60B / $20.5B market cap) — a genuinely high cash yield for a company with a fortress balance sheet.


5. Synthesis

Where the agents agree

Fundamentals, Sentiment, and Valuation all converge on: the balance sheet and cash generation are not broken — the market's fear is about the future operating model, not today's numbers. Q1 beat, margin guidance raised, buyback increased, net cash, 27% payout ratio. On a pure numbers basis this screens as statistically cheap by a wide margin.

Where the tension is real

Moat Analyst's quantitative work (gross margin -220bps, ROIC -340bps over 3 years) validates the bear case Sentiment surfaced (Berenberg's "faster-than-expected AI transition") — the moat erosion is measurable, not just narrative. This isn't a case of a good business mispriced on noise; it's a company undergoing a real, still-unresolved transition in its core economic model, that happens to also be statistically cheap. Both things are true simultaneously. Per the framework's first principle: "this is a close call because" the fair-value range assumes the AI-disruption fear is overstated relative to Cognizant's ability to adapt — a bet the data can't fully confirm yet. Give it 2-3 more quarters of bookings-mix and margin evidence before sizing up.

Portfolio concentration flag (Portfolio Strategist)

The user already holds ACN ([7.0], in buy zone, same AI-disruption-to-IT-services thesis) and EPAM (tiny position, -59%, also services-model/AI-exposed). Adding CTSH would be a third position riding the identical structural bet — that traditional IT-services/staff-augmentation survives the AI transition better than the market currently prices. This isn't diversification; it's concentration dressed as three tickers. Size CTSH accordingly — smaller than a standalone "great company, cheap" conviction would otherwise warrant.

Verdict

Conviction: 6.5/10 — Value case with real, acknowledged business-model risk. Not a value trap (cash generation, balance sheet, and capital return are genuine), but not a clean "great company, bad price" either — the moat is measurably eroding and management is mid-restructuring.

  • Entry zone: $38-45 (current price is already inside this zone). Stage in — don't go all-in given the unresolved structural question and existing ACN/EPAM correlation.
  • Add on further weakness: $35-38 if AI-disruption fear intensifies further without a fundamental deterioration (i.e., pure multiple compression = better entry).
  • Trim/avoid adding above: $60+ (top of fair-value range).
  • Thesis break: gross margin decline accelerates past -300bps/yr, Project Leap savings fail to show up in FY2026 margin guidance, or bookings growth (currently +21% quarterly, +70% large-deal TCV) reverses for 2 consecutive quarters — that would mean the AI transition is winning faster than management's own defense plan.
  • Thesis confirmation to watch: Q2 2026 earnings — bookings mix shift toward AI-native deals, margin guidance held or raised again, and whether insider buying clusters at current $40s levels (only one buy so far, at $52).

Sources: Yahoo Finance MCP (get_stock_info, get_financial_statement, get_historical_stock_prices, get_recommendations, get_holder_info, get_yahoo_finance_news); WebSearch — TS2 Tech, TIKR, Quiver Quantitative, TIKR — $2B buyback bet, Grafa — Q1 2026 results, StockTitan — Project Leap 8-K, Republic World — layoffs, PitchGrade — margin pressure research.